Appili Therapeutics Inc.
Other OTC•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Dr. Donald D. Cilla Jr., M.B.A., Pharmd
- Full Time Employees
- 8
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- #21-1344 Summer Street Halifax NS Canada B3H 0A8
- IPO Date
- Jan 8, 2021
- Website
- appilitherapeutics.com
- Similar Companies
- Business
- Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.
Company News
Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc.
Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.
Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia
Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ®™
Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025
Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025
Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders
Appili Therapeutics Announces Results of Special Meeting of Shareholders
Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
Appili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek™ 2024
Appili Therapeutics – Press Release Correction
Aditxt's Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili's Shareholder Approval
Appili Therapeutics Announces Mailing of the Management Information Circular in Connection with the Special Meeting of Shareholders
Aditxt Delivers Shareholder Update and 2024 Year-End Plan
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
Appili Therapeutics Announces Third Amendment to Arrangement Agreement and Provides Updated on Transaction with Aditxt
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2025